非清髓异基因造血干细胞移植治疗2例恶性血液病长期生存并自然生育的病例分析

目的:探讨非清髓异基因造血干细胞移植(non-myeloablative allogeneic hematopoietic stem cell transplantation, NMA allo-HSCT)对恶性血液病的疗效和生育功能的影响。方法:报道2例恶性血液病患者经NMA allo-HSCT治疗的过程及生育情况，并复习相关文献。结果:1例为25岁MDS转化的AML女性患者，1例为32岁NHL女性患者，均接受NMA allo-HSCT,截至随访日期(2022-10-01),2例患者分别无病生存190个月和115个月，且均自然生育健康子女。结论:NMA allo-HSCT治疗恶性血液病患者取得了长期生存，并保留了生育功能。

Non-myeloablative allogeneic hematopoietic stem cell transplantation for the treatment of 2 patients with hematological malignancies with long term survival and natural birth

Objective:To explore the efficacy and fertility of non-myeloablative(NMA) allogeneic hematopoietic stem cell transplantation(allo-HSCT) for hematologic malignancies.Methods:The process and fertility of 2 patients with hematologic malignancies treated with NMA allo-HSCT were reported,and the related literatures were reviewed.Results:One 25-year-old female patient with acute myeloid leukemia(AML) transformed from myelodysplastic syndrome(MDS) and one 32-year-old female patient with non Hodgkin's lymphoma(NHL) received NMA allo-HSCT treatment.Up to the follow-up date(2022-10-01),2 patients had diseases free survival with 190 months and 115 months,respectively,and both had naturally given birth to healthy children.Conclusion:NMA allo-HSCT benefited hematologic malignancies with long-term survival and preserved fertility.